PDF(Pubmed)
Abstract：
UNASSIGNED: This systematic review and meta-analysis was to evaluate the relationship between body mass index (BMI) and the clinical outcomes in patients with metastatic colorectal cancer (mCRC) undergoing treatment with bevacizumab plus chemotherapy.
UNASSIGNED: The search for relevant literature was conducted across PubMed, Embase, Cochrane Library, and Web of Science, with the final search date being October 4, 2023. We utilized the weighted mean differences (WMDs), risk ratios (RRs), or Hazard ratios (HRs) as the metric for effect sizes, which were accompanied by 95% confidence intervals (CIs).
UNASSIGNED: A total of 9 studies were included for analysis. The results indicated that non-obese patients with mCRC undergoing treatment with bevacizumab experienced a reduced overall survival (OS) at the six-month compared to their obese counterparts (RR: 0.97, 95% CI: 0.94 to 1.00, p = 0.047). Furthermore, no significant differences in one-year, two-year, and five-year OS, as well as PFS and median OS, were observed between obese and non-obese mCRC patients undergoing treatment with bevacizumab plus chemotherapy.
UNASSIGNED: These findings suggest that obesity may play a role in the short-term OS of patients with mCRC undergoing bevacizumab treatment. The clinical implications of these findings underscore the importance of considering patients\' BMI in the context of mCRC care. This study may also help guide personalized treatment strategies and further research into the interplay between obesity, treatment efficacy, and patient survival in mCRC. However, further investigation is warranted to substantiate the findings of this study.
UNASSIGNED: The search for relevant literature was conducted across PubMed, Embase, Cochrane Library, and Web of Science, with the final search date being October 4, 2023. We utilized the weighted mean differences (WMDs), risk ratios (RRs), or Hazard ratios (HRs) as the metric for effect sizes, which were accompanied by 95% confidence intervals (CIs).
UNASSIGNED: A total of 9 studies were included for analysis. The results indicated that non-obese patients with mCRC undergoing treatment with bevacizumab experienced a reduced overall survival (OS) at the six-month compared to their obese counterparts (RR: 0.97, 95% CI: 0.94 to 1.00, p = 0.047). Furthermore, no significant differences in one-year, two-year, and five-year OS, as well as PFS and median OS, were observed between obese and non-obese mCRC patients undergoing treatment with bevacizumab plus chemotherapy.
UNASSIGNED: These findings suggest that obesity may play a role in the short-term OS of patients with mCRC undergoing bevacizumab treatment. The clinical implications of these findings underscore the importance of considering patients\' BMI in the context of mCRC care. This study may also help guide personalized treatment strategies and further research into the interplay between obesity, treatment efficacy, and patient survival in mCRC. However, further investigation is warranted to substantiate the findings of this study.
摘要：
■本系统综述和荟萃分析旨在评估接受贝伐单抗联合化疗治疗的转移性结直肠癌（mCRC）患者体重指数（BMI）与临床预后之间的关系。
■搜索相关文献是在PubMed，Embase,科克伦图书馆,和WebofScience,最终搜索日期为2023年10月4日。我们利用加权平均差(WMD)，风险比(RR)，或危险比(HR)作为效果大小的度量，伴有95%置信区间(CI)。
■共纳入9项研究进行分析。结果表明，与非肥胖患者相比，接受贝伐单抗治疗的mCRC患者在六个月内的总生存期（OS）降低（RR：0.97，95％CI：0.94至1.00，p=0.047）。此外，一年没有显著差异，两年,和五年操作系统，以及PFS和中位数OS，在接受贝伐单抗联合化疗治疗的肥胖和非肥胖mCRC患者之间观察到。
■这些研究结果表明，肥胖可能在接受贝伐单抗治疗的mCRC患者的短期OS中起作用。这些发现的临床意义强调了在mCRC护理中考虑患者BMI的重要性。这项研究还可能有助于指导个性化治疗策略，并进一步研究肥胖之间的相互作用。治疗功效,和mCRC患者的生存率。然而,需要进一步调查以证实本研究的结果.
■搜索相关文献是在PubMed，Embase,科克伦图书馆,和WebofScience,最终搜索日期为2023年10月4日。我们利用加权平均差(WMD)，风险比(RR)，或危险比(HR)作为效果大小的度量，伴有95%置信区间(CI)。
■共纳入9项研究进行分析。结果表明，与非肥胖患者相比，接受贝伐单抗治疗的mCRC患者在六个月内的总生存期（OS）降低（RR：0.97，95％CI：0.94至1.00，p=0.047）。此外，一年没有显著差异，两年,和五年操作系统，以及PFS和中位数OS，在接受贝伐单抗联合化疗治疗的肥胖和非肥胖mCRC患者之间观察到。
■这些研究结果表明，肥胖可能在接受贝伐单抗治疗的mCRC患者的短期OS中起作用。这些发现的临床意义强调了在mCRC护理中考虑患者BMI的重要性。这项研究还可能有助于指导个性化治疗策略，并进一步研究肥胖之间的相互作用。治疗功效,和mCRC患者的生存率。然而,需要进一步调查以证实本研究的结果.
